Clinical trials: Lung Adenocarcinoma
Lung Cancer
Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer
This randomized phase III trial is studying carboplatin, paclitaxel, radiation therapy, and thalidomide to see how well they work compared to carboplatin, paclitaxel, and radiation therapy alone in treating patients with newly…
- Trial name
- NCT00004859
- Testing
- carboplatin, paclitaxel, thalidomide
- Where
- 236 sites in United States, South Africa
- Volunteers
- 589 people
- Sponsor
- National Cancer Institute (NCI)
Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC)
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig…
- Conditions
- Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
- Trial name
- NCT05652686
- Testing
- Peluntamig (PT217), Carboplatin + Etoposide, Paclitaxel.
- Where
- 15 sites in United States
- Volunteers
- 203 people
- Sponsor
- Phanes Therapeutics
Metastases, Neoplasm, Carcinoma, Non-small Cell Lung
A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
Study I3G-MC-JGCB (JGCB) is a multicenter, nonrandomized, open-label, dose-escalation Phase 1b study of LY2584702 in combination with either erlotinib or everolimus.
- Conditions
- Metastases, Neoplasm, Carcinoma, Non-small Cell Lung, Renal Cell Carcinoma, Neuroendocrine Tumors
- Trial name
- NCT01115803
- Testing
- LY2584702, Erlotinib, Everolimus
- Where
- 3 sites in United States, France
- Volunteers
- 29 people
- Sponsor
- Eli Lilly and Company
Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma
Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
This phase III trial studies how well nivolumab and ipilimumab works with or without local consolidation therapy in treating patients with stage IV non-small cell lung cancer.
- Conditions
- Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT03391869
- Testing
- Ipilimumab, Local Consolidation Therapy, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 339 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Solid Tumors
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)
This study will characterize the safety and tolerability and identify the recommended Phase 2 dose (RP2D) of subcutaneous (SC) ALKS 4230 as monotherapy and in combination with pembrolizumab.
- Trial name
- NCT03861793
- Testing
- ALKS 4230, Pembrolizumab
- Where
- 48 sites in United States, Canada and 4 more
- Volunteers
- 116 people
- Sponsor
- Mural Oncology, Inc
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer
Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
This randomized phase II trial is studying how well giving docetaxel together with either cetuximab or bortezomib works as first-line therapy in treating patients with stage III or stage IV non-small cell lung cancer.
- Conditions
- Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer, Malignant Pleural Effusion
- Trial name
- NCT00118183
- Testing
- docetaxel, cetuximab, bortezomib
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer, Pulmonary Complications
S0229, Pulmonary Rehabilitation Education w/wo Exercise Training in Improving Physical Function in Patients Who Are Undergoing Chemo & RT for Locally Advanced Lung Cancer
RATIONALE: Pulmonary rehabilitation education and exercise training may improve physical function and quality of life in patients who are receiving treatment for lung cancer.
- Trial name
- NCT00090961
- Testing
- educational intervention, supervised exercise program
- Where
- 60 sites in United States
- Volunteers
- 2 people
- Sponsor
- SWOG Cancer Research Network
Metastatic Breast Carcinoma, Locally Advanced Breast Cancer
Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients
Study objective: Cohort 1: To quantify the uptake of 68GaNOTA-Anti-HER2 VHH1 in local or distant metastases from breast carcinoma patients and to assess repeatability of the image-based HER2 quantification.
- Conditions
- Metastatic Breast Carcinoma, Locally Advanced Breast Cancer, Cancer of Pancreas, Solid Tumor With Intermediate or High HER2 Expression
- Trial name
- VUBAR (NCT03924466)
- Testing
- 68GaNOTA-Anti-HER2 VHH1
- Where
- Belgium
- Volunteers
- 55 people
- Sponsor
- Universitair Ziekenhuis Brussel
Hepatocellular Carcinoma, COVID-19
COVID-19 Infection in Patients With Hepatocellular Carcinoma
Since December 2019, a new disease named COVID-19 linked to a new coronavirus, SARS-CoV2 has emerged in China in the city of Wuhan, Hubei province, spreading very quickly to all 5 continents, and responsible for a pandemic.
- Trial name
- COVID19-CHIEF (NCT04367805)
- Testing
- nasopharyngeal Covid 19 RT-PCR
- Where
- France
- Volunteers
- 23 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
This study evaluates cancer-related weight and muscle mass loss, symptoms, and physical function (cachexia) in patients undergoing treatment for colorectal, lung, or pancreatic cancer that cannot be removed by surgery…
- Conditions
- Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8
- Trial name
- LOTUS (NCT06073431)
- Testing
- Biospecimen Collection, Computed Tomography, Electronic Health Record Review
- Where
- 225 sites in United States
- Volunteers
- 800 people
- Sponsor
- University of Rochester
Breast Cancer, Lung Cancer
HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer
RATIONALE: Vaccines made from the HER2/neu antigen may make the body build an immune response and kill tumor cells. Colony-stimulating factors such as GM-CSF increase the number of immune cells found in bone marrow or peripheral…
- Conditions
- Breast Cancer, Lung Cancer, Ovarian Cancer
- Trial name
- NCT00003002
- Testing
- HER-2/neu peptide vaccine, sargramostim
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Washington
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer
Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer
This phase I trial studies the side effects of soy isoflavones when given together with radiation therapy and chemotherapy in treating patients with stage IIIA-IIIB non-small cell lung cancer.
- Conditions
- Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer
- Trial name
- NCT01958372
- Testing
- soy isoflavones, cisplatin, etoposide
- Where
- 5 sites in United States
- Volunteers
- 11 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
MTAP-deleted Solid Tumors
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
This is a first-in-human Phase 1/2, multicenter, open-label study of S095035 as single-agent, or in combination with TNG462 in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP who have…
- Trial name
- NCT06188702
- Testing
- S095035, TNG462
- Where
- 20 sites in United States, Australia and 5 more
- Volunteers
- 61 people
- Sponsor
- Servier Bio-Innovation LLC
Advanced Solid Tumor, Pancreatic Adenocarcinoma
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
This is an open-label, dose-exploration and expansion study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of IMM-1-104 when administered as monotherapy or in…
- Conditions
- Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC)
- Trial name
- NCT05585320
- Testing
- IMM-1-104 Monotherapy (Treatment Group A), IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B), IMM-1-104 + modified FOLFIRINOX (Treatment Group C)
- Where
- 20 sites in United States
- Volunteers
- 209 people
- Sponsor
- Immuneering Corporation
Ovarian Cancer, Pancreas Cancer
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma.
- Conditions
- Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma, Renal Cell Carcinoma
- Trial name
- NCT06582017
- Testing
- QXL138AM Injection every 2 weeks by IV Infusion
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- Nammi Therapeutics Inc
Non-Small-Cell Lung Cancer
Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma
Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and development. It can inhibit the angiogenesis related kinase, such as VEGFR, FGFR, PDGFR, and tumor cell proliferation related kinase -c-Kit…
- Trial name
- NCT03728374
- Testing
- Anlotinib
- Volunteers
- 38 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Lung Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Can Not Be Surgically Removed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003235
- Testing
- carboplatin, paclitaxel, radiation therapy
- Where
- 6 sites in United States
- Volunteers
- 294 people
- Sponsor
- Eastern Cooperative Oncology Group
Lung Cancer
Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00028938
- Testing
- epoetin alfa, carboplatin, paclitaxel
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Wake Forest University Health Sciences
Intrahepatic Cholangiocarcinoma (Icc)
Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC
This is a multicenter, open label, randomized, two-arm clinical study to observe and evaluate the efficacy and safety of adebrelimab combined with irinotecan liposomes, 5-fluorouracil, calcium folinate ± lenvatinib as first-line…
- Trial name
- NCT06648525
- Testing
- Adebrelimab, Irinotecan liposomes, Lenvatinib
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Harbin Medical University
Lung Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00006378
- Testing
- carboplatin, paclitaxel, radiation therapy
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Case Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.